A brief profile of The Biotechnology and Biological Sciences Research Council (BBSRC). The BBSRC is the largest UK research council for non-medical biosciences, looking to dominate market in promoting public dialogue on bioscience and funding curiosity-led research, through a direct investment in bioscience research in UK universities and institutes.

logonhnIn particular BBSRC is aiming at promoting and supporting bioscience training and skills for the next generation of bio scientists with over 98M spent in knowledge exchange & skills in 2013-2014. The aim of the BBSCR is maintaining the UK at forefront of fundamental bioscience research providing the highest quality research environments, and providing the skilled people necessary for a strong science based environment.

Within BBSRC funding program three major strategic scientific priorities are taken into consideration including: agriculture and food security, industrial biotechnology & bioenergy and bioscience for health. With this in mind, they have strategic investments in 8 research institutes in the UK that focus in these areas.bbsrc

ADVERTISEMENT

The industry’s biotech & bioenergy field is focused on harnessing the extraordinary power of bioscience to achieve a society far less dependent on coal, oil and gas for energy and its industrial raw materials. According to BBSRC, this can be achieved through broad applications of industrial biotechnology: clean energy, industrial feedstock / raw materials, chemicals and biopharmaceuticals and putting emphasis on systems and synthetic approaches.

For this reason, the BBSRC has funded up to 24.5M for Networks in bioenergy in order to boost interaction between the academia and industry and Accelerate translation of research into benefits for the UK in particular.

BBSRC has a 2014-15 budget of  around €690M to support scientists, research students in universities and institutes across the UK in order to deliver quality science and a  to promote economic growth, wealth and job creation and to improve research and bioscience in the UK.

CKb-flsUwAAK6sB

Previous post

Biotech of the week: Cell2b, the Promising Portuguese Cell Therapy Biotech

Next post

Merck relinquishes Rare Disease license to instead focus on Immuno-oncology

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.